# An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC

> **NCT07669610** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 140 (estimated)

## Conditions studied

- Breast Cancer
- Triple Negative Breast Cancer (TNBC)

## Interventions

- **DRUG:** SHR- A1811
- **DRUG:** SHR-A1811+BEV

## Key facts

- **NCT ID:** NCT07669610
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2028-09-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07669610

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07669610, "An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07669610. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*